Vyome, Embryyo form partnership to pursue AI-enabled medical devices

Vyome and Embryyo sign memorandum of understanding: ©Donson/peopleimages - stock.adobe.com

Vyome Holdings Inc. and Embryyo Technologies have signed a memorandum of understanding to collaborate on developing and commercializing AI-enabled medical devices, the companies announced.

The partnership will combine Vyome’s health care industry expertise and resources with Embryyo’s medical technology capabilities, with the goal of advancing smart medical devices that could reshape disease management and treatment.

“Vyome’s vision is to partner with the smartest talent tackling the biggest health care markets along the U.S.-India corridor and across our three pillars of pharma, AI, and medical devices,” Vyome Chairman Krishna Gupta said in a statement. “AI-enabled medical devices represent a large opportunity, and the Embryyo team—helmed by Indian Institutes of Technology alums—has been working in this sector for a decade.”

Embryyo, based in India, is building a portfolio of devices in areas including interventional oncology, surgery, wearables, and drug delivery. Co-founder and CEO Nishant Kumar said Vyome’s access to global capital markets and the U.S. health care ecosystem would help accelerate the company’s work.

As part of the collaboration, the two firms plan to host a global AI-enabled medical device innovation forum for companies along the U.S.-India corridor.

The memorandum of understanding is non-binding and subject to further conditions.

Advances in AI-enabled medical devices

Artificial intelligence is reshaping the medical device industry, creating new opportunities for personalized care, earlier diagnosis, and improved patient outcomes. Devices equipped with AI can process and interpret vast amounts of data in real time, offering clinicians insights that were previously unattainable.

One area of rapid development is imaging and diagnostics. AI-powered tools are increasingly being integrated into radiology, pathology, and ophthalmology devices, where they can detect subtle patterns or anomalies that the human eye might miss. These advances hold promise for earlier detection of cancers, cardiovascular disease, and neurological conditions.

Surgical and interventional technologies are also benefiting from AI integration. Smart systems can assist surgeons with precision navigation, reduce the risk of complications, and shorten recovery times. Similarly, AI-enabled wearables and remote monitoring devices are helping track chronic conditions, offering continuous data streams that inform treatment decisions and alert clinicians to potential issues before they become emergencies.

Drug delivery is another frontier. Devices that use AI to tailor dosage and timing to individual patient needs could improve adherence and effectiveness while reducing side effects. This approach aligns with the broader push toward precision medicine, where treatments are customized based on patient-specific data.

As regulatory bodies adapt to the evolving landscape, challenges remain around safety, transparency, and data privacy. Still, experts say the convergence of AI and medical devices is poised to redefine standards of care globally, with the potential to ease healthcare burdens, expand access, and improve outcomes across a wide range of conditions.